Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human ABBV-155 alone and with taxanes in relapsed/refractory solid tumors
NL-OMON55246Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mirzotamab clezutoclax in small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), breast cancer and 1 more (4 arms), sponsored by AbbVie Inc. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 2 more. Started Mar 2021; status: recruiting.
02
Drugs
mirzotamab clezutoclax
03
Conditions
small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)breast cancerNonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON55246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55246.